Moderna Tumbles 25% After Apparent Early Leak of Melanoma Vaccine Data; BioNTech Dips, Pfizer Edges Higher
Moderna's stock dropped 25% after leaked melanoma vaccine data was posted and then removed. The data suggested the vaccine, developed with Merck, reduced recurrence or death risk. Moderna shares are still up 526% YTD. BioNTech fell 2%, while Pfizer rose 0.9%. The full results are expected at the ESMO Congress on October 24.
How this was made
The 30-second read
Why it matters
The leak caused a 25% drop in Moderna stock, with limited spillover to peers; the biotech sector shows modest weakness.
Market read
The event is a material, first‑report disclosure that moved a major biotech stock sharply, creating immediate trading relevance.
What to watch
Potential regulatory scrutiny over the premature leak and the impact on Merck's partnership could add further volatility.
Background
A melanoma vaccine trial result was briefly posted online and removed before the scheduled ESMO presentation, prompting a rapid market reaction.
Ticker impact
Moderna shares fell 25% after a prematurely posted melanoma vaccine report was quickly removed, marking the first public disclosure of the leaked data.
likely continued pressure as the market prices in uncertainty over the trial outcome
The 25% intraday drop and the absence of any mitigating news indicate a strong negative reaction that may persist until official ESMO data are released.
Market effects
Biotech sector faces broader risk aversion; iShares Biotechnology ETF (IBB) down 2% as investors weigh the fallout.
U.S. market sees modest drag, with S&P 500 ETF (SPY) down 1.3% following the sell‑off.
The leak may influence global biotech valuations, especially peers developing mRNA cancer therapies.
Counterpoint
If the full ESMO presentation confirms the favorable data, the sell‑off could be a buying opportunity at a discounted price.
Key entities
- companyModerna
Developer of the melanoma vaccine; primary subject of the article.
